All In MedTech

FDA Clearance Tracker · P080014

CERVISTA HPV HR AND GENFIND DNA EXTRACTION KIT

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Mar 12, 2009 (this decision)Source: openFDAMethods & limitations

PMA

The decision

FDA number
P080014
Device name
CERVISTA HPV HR AND GENFIND DNA EXTRACTION KIT
Applicant
Hologic, Inc.
Applicant location
Marlborough, MA
Received
Apr 28, 2008
Decided
Mar 12, 2009
Decision
Approval withdrawn
Supplements
24 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MAQ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE CERVISTA HPV HR AND GENFIND DNA EXTRACTION KIT. CERVISTA HPV HR INDICATIONS FOR USE: THE CERVISTA HPV HR TEST IS AN IN VITRO DIAGNOSTIC TEST FOR THE QUALITATIVE DETECTION OF DNAFROM 14 HIGH-RISK- HUMAN PAPILLOMAVIRUS (HPV) TYPES (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,59, 66, AND 68) IN CERVICAL SPECIMENS. THE CERVISTA HPV HR TEST CANNOT DETERMINE THESPECIFIC HPV TYPE PRESENT.THE CERVISTA HPV HR TEST USES THE INVADER CHEMISTRY, A SIGNAL AMPLIFICATION METHOD FORDETECTION OF SPECIFIC NUCLEIC ACID SEQUENCES. THIS METHOD USES TWO TYPES OF ISOTHERMAL REACTIONS:A PRIMARY REACTION THAT OCCURS ON THE TARGETED DNA SEQUENCE AND A SECONDARY REACTION THAT PRODUCES A FLUORESCENT SIGNAL. THE CERVISTA HPV HR TEST IS INDICATED:1) TO SCREEN PATIENTS WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE (ASCUS)CERVICAL CYTOLOGY RESULTS TO DETERMINE THE NEED FOR REFERRAL TO COLPOSCOPY.2) IN WOMEN 30 YEARS AND OLDER THE CERVISTA HPV HR TEST CAN BE USED WITH CERVICALCYTOLOGY TO ADJUNCTIVELY SCREEN TO ASSESS THE PRESENCE OR ABSENCE OF HIGH-RISK HPVTYPES. THIS INFORMATION, TOGETHER WITH THE PHYSICIAN'S ASSESSMENT OF CYTOLOGY HISTORY,OTHER RISK FACTORS, AND PROFESSIONAL GUIDELINES, MAY BE USED TO GUIDE PATIENTMANAGEMENT. CERVICAL SPECIMENS THAT MAY BE TESTED WITH THE CERVISTA HPV HR TEST INCLUDE THE FOLLOWINGPRESERVATION SYSTEM COLLECTION MEDIA AND COLLECTION DEVICES:¿ THINPREP PAP TEST PRESERVCYT SOLUTION¿ BROOM-TYPE DEVICE (E.G. ROVERS CERVEX BRUSH, WALLACH PAPETTE), OR ENDOCERVICALBRUSH/SPATULA.GENFIND DNA EXTRACTION KIT INDICATION FOR USE:THE GENFIND DNA EXTRACTION KIT IS INTENDED FOR USE IN THE EXTRACTION OF DNA FROMCERVICAL SPECIMENS COLLECTED IN THINPREP PAP TEST PRESERVCYT SOLUTION FOR TESTINGBY THE CERVISTA HPV HR AND CERVISTA HPV 16/18 TESTS.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MAQ. The earliest in FDA's data is P880009, decided Dec 23, 1988.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Hologic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.